<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1103210599
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ketorolac BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        KETOROLAC TROMETHAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        313.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ketorolac belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs).<br />Ketorolac Tromethamine is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ketorolac Tromethamine TBM if you:</strong></p><p>&bull; are allergic to the active substance (ketorolac) or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull; are allergic to aspirin or other NSAIDs.</p><p>&bull; have had or are planning to have heart bypass surgery</p><p>&bull; have severe uncontrolled heart failure</p><p>&bull; have asthma</p><p>&bull; have nasal polyps syndrome, angioedema or bronchospasm (breathing difficulties)</p><p>&bull; have a history of Stevens- Johnsons Syndrome (a rare skin condition with severe blisters and bleeding in the lips, eyes, mouth, nose and genitals).</p><p>&bull; have bleeding in the brain or other bleeding disorders</p><p>&bull; are at 28 weeks of pregnancy or more</p><p>&bull; are in labour and delivery</p><p>&bull; are breastfeeding or planning to breastfeed</p><p>&bull; have active ulcer or bleeding from the stomach or gut</p><p>&bull; have inflammatory bowel disease (Crohn&rsquo;s Disease or Ulcerative Colitis)</p><p>&bull; have liver or kidney disease</p><p>&bull; have high potassium in the blood</p><p>&bull; are having central nervous system injection e.g. epidural, brain or spinal administration</p><p>&bull; are going into have any major surgery</p><p>&bull; are using the following medicines</p><p>➢ other NSAIDs.</p><p>➢ Probenecid</p><p>➢ Lithium</p><p>➢ Pentoxyphylline</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking this medicine. If you have, or previously had, any of the following medical conditions, see your health care provider to discuss treatment options other than Ketorolac Tromethamine TBM:</p><p>&bull; Heart Attack or Angina</p><p>&bull; Stroke or Mini-stroke</p><p>&bull; Loss of Vision</p><p>&bull; Current Pregnancy (less than 29 weeks)</p><p>&bull; Congestive Heart Failure</p><p>Patients who took a drug in the same class as Ketorolac Tromethamine TBM after a type of heart surgery (coronary artery bypass grafting (CABG)) were more likely to have heart attacks, strokes, blood clots in the leg(s) or lung(s), and infections or other complications than those who did NOT take that drug. Ketorolac Tromethamine TBM should NOT be used in patients under 18 years of age since the safety and effectiveness have NOT been established</p><p>BEFORE taking this medication, tell your health care provider if you have any of the following:</p><p>&bull; High blood pressure</p><p>&bull; High cholesterol</p><p>&bull; Diabetes mellitus or on a low sugar diet</p><p>&bull; Thickening or hardening of your artery walls (Atherosclerosis)</p><p>&bull; Poor circulation to your extremities</p><p>&bull; Smoker or ex-smoker</p><p>&bull; Kidney disease or urine problems</p><p>&bull; Previous ulcer or bleeding from the stomach or gut</p><p>&bull; Previous bleeding in the brain</p><p>&bull; Bleeding problems</p><p>&bull; Liver, biliary, pancreatic or renal problems</p><p>&bull; Family history of allergy to NSAIDs.</p><p>&bull; Family history of asthma, nasal polyps, long-term swelling of the sinus (chronic sinusitis) or hives</p><p>&bull; Family history of allergy to sulphonamide drugs (if applicable)</p><p>&bull; Any other medical problem</p><p>&bull; Planned a heart surgery.<br />Also, before taking this medication, tell your health care provider if you are planning to get pregnant</p><p><strong>Other medicines and Ketorolac Tromethamine TBM</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes prescription as well as non-prescription medication. Tell your doctors if you are taking any of the below mentioned medication:</p><p>&bull; Acetylsalicylic Acid (ASA) or other NSAIDs (e.g. ASA, celecoxib, diclofenac, ibuprofen, indomethacin, ketorolac, meloxicam, naproxen).</p><p>&bull; Antacids</p><p>&bull; Antidepressants</p><p>&bull; Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. citalopram, fluoxetine, paroxetine, sertraline)</p><p>&bull; Blood pressure medications</p><p>➢ ACE (angiotensin converting enzyme) inhibitors (e.g. enalapril, lisinopril, perindopril, Ramipril)</p><p>➢ ARBs (angiotensin II receptor blockers) (e.g. candesartan, irbesartan, losartan, valsartan)</p><p>&bull; Blood thinners (e.g. warfarin, ASA, clopidogrel) &bull; Corticosteroids (including glucocorticoids) (e.g. prednisone)</p><p>&bull; Cyclosporine</p><p>&bull; Digoxin</p><p>&bull; Diuretics e.g. furosemide, hydrochlorothiazide</p><p>&bull; Lithium</p><p>&bull; Methotrexate</p><p>&bull; Morphine</p><p>&bull; Oxpentifylline</p><p>&bull; Probenecid</p><p>Your health care provider may prescribe low dose ASA as a blood thinner to reduce your risk of having a heart attack or stroke while you are taking Ketorolac Tromethamine TBM. Take only the amount of ASA prescribed by your health care provider. You are more likely to upset or damage your stomach if you take both Ketorolac Tromethamine TBM and ASA than if you took Ketorolac Tromethamine TBM alone</p><p><strong>Ketorolac Tromethamine TBM with food and drink</strong></p><p>Do NOT drink alcoholic beverages while taking this medication because you would be more likely to develop stomach problem.</p><p><strong>Fertility, Pregnancy, Labour, and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, or pharmacist for advice before taking this medicine.</p><p>Fertility may be decreased. The use of Ketorolac Tromethamine TBM is not recommended in women trying to get pregnant. In women who have difficulty conceiving, stopping Ketorolac Tromethamine TBM should be considered.</p><p>In late pregnancy, Ketorolac Tromethamine TBM should be avoided because it may cause premature closure of the ductus arteriosus.</p><p>The use of ketorolac tromethamine in labour and delivery is contraindicated because it may adversely affect foetal circulation and inhibit uterine contractions.</p><p>The use of ketorolac tromethamine is contraindicated in nursing mothers because ketorolac tromethamine is excreted in human milk leading to the potential adverse effects of prostaglandininhibiting drugs on neonates.</p><p><strong>Driving and using machines</strong></p><p>Ketorolac Tromethamine TBM may cause you to become drowsy or tired. Be careful about driving or participating in activities that require you to be alert.<br />If you become drowsy, dizzy or light-headed after taking Ketorolac Tromethamine TBM, do NOT drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Ketorolac Tromethamine TBM will always be prepared and given to you intravenously (into a vein) or intramuscularly (into the muscles) by a doctor or another healthcare professional. Check with your doctor or pharmacist if you are not sure how this medication will be given to you.</p><p><strong>How much will be given</strong></p><p>Ketorolac Tromethamine TBM is NOT recommended for use in patients under 18 years of age since safety and effectiveness have NOT been established. Recommended dosage is:</p><table border="1" cellspacing="1" cellpadding="1" style="width:906px"><tbody><tr><td rowspan="2" colspan="1" style="text-align:center; width:160px"><strong>Route</strong></td><td rowspan="1" colspan="2" style="text-align:center; width:179px"><strong>Single dose</strong></td><td rowspan="1" colspan="2" style="text-align:center; width:184px"><strong>Multiple dose</strong></td></tr><tr><td style="text-align:center; width:179px"><strong>Adults &lt; 65 years of age</strong></td><td style="text-align:center; width:188px"><strong>Adults &ge; 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight</strong></td><td rowspan="2" colspan="1" style="text-align:center; width:184px"><strong>Adults &lt; 65 years of age</strong><br />&nbsp;</td><td rowspan="2" colspan="1" style="text-align:center; width:192px"><strong>Adults &ge; 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight</strong><br />&nbsp;</td></tr><tr><td style="text-align:center; width:160px"><strong>Intravenous (IV)</strong></td><td style="text-align:center; width:179px">One dose of 30 mg</td><td style="text-align:center; width:188px">One dose of 15 mg</td></tr><tr><td style="text-align:center; width:160px"><strong>Intramascular (IM)</strong></td><td style="text-align:center; width:179px">One dose of 6. mg</td><td style="text-align:center; width:188px">One dose of 30 mg</td><td style="text-align:center; width:184px">30 mg every 6 hours (maximum dose not more than 120 mg)</td><td style="text-align:center; width:192px">15 mg every 6 hours (maximum dose not Intramuscular more than 600 mg)</td></tr></tbody></table><p>Take Ketorolac Tromethamine TBM only as directed by your health care provider. <strong>Do NOT take more of it, do NOT take it more often and do NOT take it for a longer period of time than your health care provider recommended. If possible, you should take the lowest dose of this medication for the shortest time period</strong></p><p><strong>If you are given more Ketorolac Tromethamine TBM than you should be given</strong></p><p>As your healthcare provider will be monitoring your condition carefully it is unlikely that you will be given too much Ketorolac Tromethamine TBM. Too much Ketorolac Tromethamine TBM may increase your chances of unwanted and sometimes dangerous side effects, especially if you are elderly, have other diseases or take other medications.</p><p>Symptoms of overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and abdominal pain, which are generally reversible with supportive care. Tell your healthcare provider if you experience any of these mentioned symptoms.</p><p>In general, combined duration of use of ketorolac tromethamine injection and ketorolac tromethamine tablets is not to exceed 5 (five) days, because of the increased risk of serious adverse events.</p><p>Do NOT give it to anyone else. It may harm them, even if their symptoms seem to be similar to yours.</p><p><strong>If you forget to use Ketorolac Tromethamine TBM</strong></p><p>The missed dose should be taken as soon as remembered, and then the regular dosing schedule should be continued. Two doses of Ketorolac Tromethamine TBM should not be taken at the same time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Ketorolac Tromethamine TBM may cause some side effects, especially when used for a long time or in large doses. When these side effects occur, you may require medical attention. Report all symptoms or side effects to your health care provider. Ketorolac Tromethamine TBM may cause you to become more sensitive to sunlight. Any exposure to sunlight or sunlamps may cause sunburn, skin blisters, skin rash, redness, itching or discolouration, or vision changes. If you have a reaction from the sun, check with your health care provider.</p><p>Check with your health care provider <strong>immediately</strong> if you develop chills, fever, muscle aches or pains, swelling of the face and/or throat, or other flu-like symptoms, especially if they occur before or together with a skin rash. These symptoms may be the first signs of a <strong>serious allergic reaction</strong> to this medication. You may need urgent medical treatment.</p><p>Ketorolac tromethamine is a potent NSAID and may cause serious side effects such as gastrointestinal bleeding or kidney failure, which may result in hospitalisation and even fatal outcome. Remember that the total combined duration of use of oral ketorolac tromethamine and&nbsp;IV or IM dosing of ketorolac tromethamine is not to exceed 5 days in adults. Ketorolac tromethamine is not indicated for use in paediatric patients. Also, ketorolac tromethamine may be cleared more slowly by the elderly who are also more sensitive to the dose-related adverse effects of NSAIDs. Extreme caution and reduced dosages and careful clinical monitoring must be used when treating the elderly with ketorolac tromethamine.</p><p>STOP taking drug and get emergency medical attention <strong>immediately </strong>if you notice any of the following:</p><p>&bull; Bloody or black tarry stools</p><p>&bull; Shortness of breath, wheezing, any trouble breathing, or chest tightness</p><p>&bull; Skin rash, hives, swelling or itching</p><p>&bull; Blurred vision, or any visual disturbance</p><p>&bull; Any change in the amount or colour of your urine (red or brown)</p><p>STOP taking drug and talk to your doctor or pharmacist if you notice any of the following:</p><p>&bull; Any pain or difficulty experienced while urinating</p><p>&bull; Swelling of the feet, lower legs, weight gain</p><p>&bull; Vomiting or persistent indigestion, nausea, stomach pain or diarrhoea</p><p>&bull; Yellow discolouration of the skin or eyes, with or without itchy skin</p><p>&bull; Malaise, fatigue, loss of appetite</p><p>&bull; Headaches, stiff neck</p><p>&bull; Mental confusion, depression</p><p>&bull; Dizziness, light-headedness</p><p>&bull; Hearing problems</p><p>This is not a complete list of side effects. For any unexpected effects while taking Ketorolac Tromethamine TBM, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Shelf life of this product is 24 months. Do not use this medicine after the expiry date which is stated on the carton and the blister pack. The expiry date refers to the last day of that month.</p><p>&bull; Store below 30&deg;C. Retain in carton until time of use. Protect from light.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient of this product is Ketorolac Tromethamine.</p><p>&bull; The other ingredients are: ethanol, sodium chloride, hydrochloric acid,sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ketorolac Tromethamine TBM is a clear, colourless to slightly yellow colour solution, free from visible particulates, presented in 2 mL amber tubular Type I glass vial, stoppered with 13 mm.
Dark Grey coloured bromo butyl rubber stoppers and sealed with 13 mm aluminium flip off seals.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company,</p><p>Sudair Industrial Zone,</p><p>Sudair,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XXXX
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي كيتورولاك<strong>&nbsp;</strong>إلى مجموعة الأدوية المعروفة باسم الأدوية المضادة للالتهابات غير الستيروئيدية (مضادات الالتهاب غير الستيروئيدية).</p><p dir="RTL">يوصف كيتورولاك تروميثامين للألم الحاد معتدل الشدة ولمدة قصيرة (تصل حتى 5 أيام لدى البالغين).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ كيتورولاك تروميثامين تي بي إم إذا:</strong></p><p dir="RTL">&bull; كانت لديك حساسية من المادة الفعالة (كيتورولاك) أو من أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&bull; كانت لديك حساسية من الأسبرين أو مضادات الالتهاب غير الستيروئيدية الأخرى.</p><p dir="RTL">&bull; كنت قد خضعت أو تخطط لإجراء عملية جراحية في القلب.</p><p dir="RTL">&bull; كنت تعاني من قصور شديد في القلب غير منضبط.</p><p dir="RTL">&bull; كنت مصاباً بالربو.</p><p dir="RTL">&bull; كانت لديك متلازمة الورم الحميد في الأنف، وذمة وعائية أو تشنج قصبي (صعوبات في التنفس).</p><p dir="RTL">&bull; كان لديك قصة مرض&nbsp;&nbsp;من متلازمة ستيفنس- جونسون (وهي حالة جلدية نادرة مع بثور شديدة ونزيف في الشفاه, العينين, الفم, الأنف والأعضاء التناسلية).</p><p dir="RTL">&bull; كان لديك نزيف في المخ أو اضطرابات نزيف أخرى.</p><p dir="RTL">&bull; كنت بعُمر 28 أسبوعاً من الحمل أو أكثر.</p><p dir="RTL">&bull; كنت في المخاض والولادة.</p><p dir="RTL">&bull; كنت في الرضاعة الطبيعية أو تخططين للرضاعة الطبيعية.</p><p dir="RTL">&bull; كنت مصاباً بقرحة نشطة أو بنزيف من المعدة أو الأمعاء.</p><p dir="RTL">&bull; كان لديك مرض التهاب الأمعاء (مرض كرون أو التهاب القولون التقرحي).</p><p dir="RTL">&bull; كان لديك مرض في الكبد أو الكلى.</p><p dir="RTL">&bull; كان لديك نسبة عالية من البوتاسيوم في الدم.</p><p dir="RTL">&bull; كنت قد أخذت حقنة في الجهاز العصبي المركزي مثلاً: فوق الجافية، الدماغ أو العمود الفقري.</p><p dir="RTL">&bull; كنت ستجري أي عمل جراحي كبير.</p><p dir="RTL">&bull; كنت تستخدم الأدوية التالية:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- مضادات الالتهاب غير الستيروئيدية الأخرى.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- بروبينيسيد.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- ليثيوم.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- بينتوكسيفيللين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء:</p><p dir="RTL">إذا كان لديك، أو سبق أن كان لديك أياً من الحالات الطبية التالية، راجع مقدم الرعاية الصحية لمناقشة خيارات المعالجة الأخرى بغير دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>:</p><p dir="RTL">&bull; نوبة قلبية أو ذبحة صدرية.</p><p dir="RTL">&bull; سكتة دماغية أو سكتة دماغية مصغرة.</p><p dir="RTL">&bull; فقدان الرؤية.</p><p dir="RTL">&bull; حمل حالي (أقل من 29 أسبوعاً).</p><p dir="RTL">&bull; فشل قلب احتقاني.</p><p dir="RTL">المرضى الذين تناولوا دواءً من نفس فئة&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>بعد إجراء نوع من العمليات الجراحية في القلب مثل (ترقيع الشريان التاجي&nbsp;CABG) هم أكثر عرضة للإصابة بأزمات قلبية, سكتات دماغية, جلطات دموية في الساقين أو الرئتين, وبالتهابات أو غيرها من المضاعفات من أولئك الذين&nbsp;<strong>لم يتناولوا</strong>&nbsp;هذا الدواء. لا ينبغي أن يُستخدم&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>لدى المرضى الذين هم دون الـ 18 سنة من العمر, لأن السلامة والفعالية&nbsp;<strong>لم</strong>&nbsp;تثبت بعد.</p><p dir="RTL"><strong>قبل</strong>&nbsp;أخذ هذا الدواء، أخبر مقدم الرعاية الصحية الخاص بك إذا كان لديك أياً مما يلي:</p><p dir="RTL">&bull; ضغط دم مرتفع.</p><p dir="RTL">&bull; دهون مرتفعة.</p><p dir="RTL">&bull; مرض السكري أو أنك تتبع نظام غذائي منخفض السكر.</p><p dir="RTL">&bull; سماكة أو تصلب في جدران الشرايين (تصلب الشرايين).</p><p dir="RTL">&bull; ضعف الدورة الدموية في أطرافك.</p><p dir="RTL">&bull; مدخن أو مدخن سابق.</p><p dir="RTL">&bull; مرض كلوي أو مشاكل بولية.</p><p dir="RTL">&bull; قرحة سابقة أو نزيف من المعدة أو الأمعاء.</p><p dir="RTL">&bull; نزيف سابق في المخ.</p><p dir="RTL">&bull; مشاكل نزفية.</p><p dir="RTL">&bull; مشاكل في الكبد, الصفراء, البنكرياس أو الكلى.</p><p dir="RTL">&bull; قصة حساسية عائلية تجاه مضادات الالتهاب غير الستيروئيدية.</p><p dir="RTL">&bull; قصة حساسية عائلية من الربو، الزوائد الأنفية، تورم الجيوب الأنفية طويل الأمد (التهاب الجيوب الأنفية المزمن) أو الشَّرى.</p><p dir="RTL">&bull; قصة حساسية عائلية تجاه أدوية السولفوناميد (إن وجدت).</p><p dir="RTL">&bull; أية مشكلة طبية أخرى.</p><p dir="RTL">&bull; التخطيط لجراحة القلب.</p><p dir="RTL">أيضاً، قبل أخذ هذا الدواء، أخبر مقدم الرعاية الصحية لديك إذا كنت تخطط للحمل.</p><p dir="RTL"><strong>أدوية أخرى و كيتورولاك تروميثامين تي بي إم</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو قد أخذت مؤخراً, أو قد تأخذ أية أدوية أخرى. وهذا يشمل أدوية الوصفات الطبية وكذلك الأدوية التي بدون وصفات طبية.</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أيّاً من الأدوية المذكورة أدناه:</p><p dir="RTL">&bull; حمض أسيتيل ساليسيليك (ASA) أو مضادات الالتهاب غير الستيروئيدية الأخرى (مثل: حمض أسيتيل ساليسيليك, سيليكوكسيب، ديكلوفيناك، آيبوبروفين، إندوميثاسين، كيتورولاك، ميلوكسيكام، نابروكسين).</p><p dir="RTL">&bull; مضادات حموضة.</p><p dir="RTL">&bull; مضادات اكتئاب.</p><p dir="RTL">&bull; مثبطات امتصاص السيروتونين الانتقائية (SSRIs), (مثل: سيتالوبرام، فلوكسيتين، باروكسيتين، سيرترالين).</p><p dir="RTL">&bull; أدوية ضغط الدم.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- مثبطات&nbsp;ACE&nbsp;(الإنزيم المحول للأنجيوتنسين), (مثل: إينالابريل، ليزينوبريل، بيريندوبريل، راميبريل).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;- حاصرات&nbsp;ARBs&nbsp;(حاصرات مستقبلات أنجيوتنسين&nbsp;II), (مثل: كانديزارتان, إربيزارتان, لوزارتان, فالزارتان)&nbsp;</p><p dir="RTL">&bull; مميعات الدم (مثل: وارفارين، حمض أسيتيل ساليسيليك, كلوبيدوكريل).</p><p dir="RTL">&bull; ستيرويدات قشرية (بما في ذلك الجلوكوكورتيكوئيدات) (مثل: بريدنيزون).</p><p dir="RTL">&bull; سيكلوسبورين.</p><p dir="RTL">&bull; ديجوكسين.</p><p dir="RTL">&bull; مدرات البول (مثل: فوروسيميد، هايدروكلوروثيازيد).</p><p dir="RTL">&bull; ليثيوم.</p><p dir="RTL">&bull; ميثوتريكسات.</p><p dir="RTL">&bull; مورفين.</p><p dir="RTL">&bull; أوكسبنتيفيللين.</p><p dir="RTL">&bull; بروبينيسيد.</p><p dir="RTL">قد يصف مقدم الرعاية الصحية الخاص بك جرعة منخفضة من حمض أسيتيل ساليسيليك باعتباره مميع للدم من أجل تقليل خطر الإصابة بنوبة قلبية أو سكتة دماغية أثناء تناولك دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم.</strong></p><p dir="RTL">تناول فقط المقدار الذي يصفه لك مقدم الرعاية الصحية من حمض أسيتيل ساليسيليك. فأنت أكثر عرضة للإنزعاج أو التلف في المعدة, إذا أخذت كلا الدوائين&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;وحمض أسيتيل ساليسيليك من أن تأخذ دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>لوحده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيتورولاك تروميثامين تي بي إم مع الطعام والشراب</strong></p><p dir="RTL"><strong>لا تتناول</strong>&nbsp;المشروبات الكحولية أثناء أخذك هذا الدواء لأنك ستكون أكثر عرضة للإصابة بمشاكل في المعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة, الحمل, الولادة, والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة، تعتقدين أنك قد تكوني حاملة أو أنك تخططين لإنجاب طفل، اسألي طبيبك, أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">قد تنخفض الخصوبة. لا ينصح باستخدام دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>لدى النساء اللواتي يحاولن الحمل. أما لدى النساء اللواتي يجدن صعوبة في الحمل، يجب النظر بإيقاف دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>.</p><p dir="RTL">في أواخر الحمل، يجب تجنب استخدام&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;لأنه قد يتسبب بإغلاق مبكر للقناة الشريانية.</p><p dir="RTL">يُمنع استخدام كيتورولاك تروميثامين<strong>&nbsp;</strong>في المخاض والولادة, لأنه قد يؤثر سلباً على الدورة الدموية للجنين ويمنع تقلصات الرحم.</p><p dir="RTL">يُمنع استخدام كيتورولاك تروميثامين<strong>&nbsp;</strong>في الأمهات المرضعات لأن كيتورولاك تروميثامين يفرز في الحليب البشري مما يؤدي إلى تأثيرات سلبية محتملة مثبطة للبروستاغلاندين على حديثي الولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;النعاس أو التعب. كن حذراً عند القيادة أو المشاركة في أنشطة تتطلب منك أن تكون بحالة تأهب. إذا شعرت بالنعاس, الدوار, أو الدوخة بعد تناول&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>،&nbsp;<strong>لا تقود</strong>&nbsp;السيارة أو تشغل الآليات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك تماماً. إن دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>يتم تحضيره وإعطاؤه لك دائماً عن طريق الوريد (في الوريد) أو عن طريق العضل (في العضلات) وذلك من قبل طبيب أو أخصائي رعاية صحية آخر. تحقق مع طبيبك أو الصيدلي إذا لم تكن متأكداً من كيفية إعطاء هذا الدواء لك.</p><p dir="RTL"><strong>ما الكمية التي ستُعطى لك</strong></p><p dir="RTL"><strong>لا يُوصى</strong>&nbsp;باستخدام&nbsp;<strong>كيتورولاك تروميثامين تي بي إم&nbsp;</strong>لدى المرضى دون الـ 18 سنة من العمر, نظراً لعدم ثبوت السلامة والفعالية.</p><p dir="RTL">الجرعة الموصى بها هي:</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p dir="RTL"><strong>الطريـــق</strong></p></td><td colspan="2"><p dir="RTL"><strong>جرعـــة واحـــدة</strong></p></td><td colspan="2"><p dir="RTL"><strong>جرعـــة متعـــددة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>البالغـــــون</strong></p><p dir="RTL"><strong>أقل من 65 عاماً</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون من العمر 65 عاماً، والذين يعانون من ضعف كلوي و/أو أقل من 50 كغ (110 لبرة) من وزن الجسم.</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغـــــون</strong></p><p dir="RTL"><strong>أقل من 65 عاماً</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون من العمر 65 عاماً، والذين يعانون من ضعف كلوي و/أو أقل من 50 كغ (</strong>110<strong>&nbsp;لبرة) من وزن الجسم.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>عن طريق الوريد (</strong><strong>IV</strong><strong>)</strong></p></td><td style="vertical-align:top"><p dir="RTL">جرعة واحدة</p><p dir="RTL">من 30 ملغ</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">جرعة واحدة</p><p dir="RTL">من 15 ملغ</p><p dir="RTL">&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p dir="RTL">30 ملغ كل 6 ساعات</p><p dir="RTL">(الجرعة القصوى لا تتجاوز 120 ملغ)</p></td><td rowspan="2" style="vertical-align:top"><p dir="RTL">15 ملغ كل 6 ساعات</p><p dir="RTL">(الجرعة القصوى لا تتجاوز 600 ملغ)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>عن طريق العضل (</strong><strong>IM</strong><strong>)</strong></p></td><td style="vertical-align:top"><p dir="RTL">جرعة واحدة</p><p dir="RTL">من&nbsp;60&nbsp;ملغ</p></td><td style="vertical-align:top"><p dir="RTL">جرعة واحدة</p><p dir="RTL">من 30 ملغ</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">تناول دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;فقط وفقاً لتوجيهات مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL"><strong>لا تأخذ أكثر من ذلك، لا تأخذه في أحيانٍ كثيرةٍ, ولا تأخذه لفترةٍ أطولَ من الوقت الذي أوصاك به مقدم الرعاية الصحية. وإن أمكن، يجب أن تأخذ أقل جرعة من هذا الدواء لأقصر فترة زمنية.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أعطيتَ دواء كيتورولاك تروميثامين تي بي إم أكثر مما يجب</strong></p><p dir="RTL">بما أن مقدم الرعاية الصحية الخاص بك سوف يراقب حالتك بعناية، فمن غير المحتمل أن تُعطى الكثير من&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>. إن أخذك الكثير من&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;قد يزيد من فُرَص التأثيرات الجانبية غير المرغوبة والخطيرة في بعض الأحيان، خاصة إذا كنت من كبار السن، ولديك أمراض أخرى أو تتناول أدوية أخرى.</p><p dir="RTL">تقتصر أعراض الجرعة الزائدة عادةً على خمول, نعاس, غثيان, قيء, وآلام في البطن، والتي يمكن إزالتها عموماً بالرعاية الداعمة. أخبر مقدم الرعاية الصحية إذا كنت تواجه أياً من هذه الأعراض المذكورة.</p><p dir="RTL">عموماً، لا يجب أن تتجاوز مدة الاستخدام بمشاركة حُقَن كيتورولاك تروميثامين وأقراص كيتورولاك تروميثامين (الخمسة) أيام، بسبب زيادة خطر حدوث أحداث سلبية خطيرة.</p><p dir="RTL"><strong>لا تعطيه</strong>&nbsp;لأشخاصٍ آخرين. قد يضرُّ بهم، حتى لو كانت أعراضهم تبدو مشابهة لأعراضك.</p><p dir="RTL"><strong>إذا نسيت استخدام كيتورولاك تروميثامين تي بي إم</strong></p><p dir="RTL">يجب أن تؤخذ الجرعة الفائتة بمجرد تذكرها، ومن ثم يجب أن يستمر جدول الجرعات كالمعتاد. لا ينبغي أن تؤخذ جرعتين من&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;في نفس الوقت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">قد يسبب&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;بعض التأثيرات الجانبية، خصوصاً عند استخدامه لفترة طويلة أو بجرعات كبيرة. عندما تحدث هذه التأثيرات الجانبية، قد تحتاج إلى عناية طبية. يجب إبلاغ مقدم الرعاية الصحية الخاص بك عن جميع الأعراض أو التأثيرات الجانبية.</p><p dir="RTL">قد يجعلك&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;أكثر حساسية لأشعة الشمس. فإن أي تعرض لأشعة الشمس أو للمصابيح الشمسية قد يسبب حروق الشمس, ظهور بثور, طفح جلدي, احمرار, حكة أو تغير اللون, أو تغيرات في الرؤية. فإذا كان لديك رد فعل من الشمس، استشر مقدم الرعاية الصحية الخاص بك.</p><p dir="RTL">تحقق مع مقدم الرعاية الصحية الخاص بك&nbsp;<strong>على الفور</strong>&nbsp;ما إذا كنت تعاني من قشعريرة, حمى, أوجاع أو آلام بالعضلات, تورم في الوجه و/أو الحلق, أو أية أعراض أخرى شبيهة بالأنفلونزا، خاصة إذا حدثت قبل أو مع طفح جلدي. قد تكون هذه الأعراض هي أول علامات&nbsp;<strong>رد فعل تحسسي خطير</strong>&nbsp;لهذا الدواء. قد تحتاج إلى علاج طبي عاجل.</p><p dir="RTL">إن كيتورولاك تروميثامين هوعبارة عن مضاد التهاب قوي غير ستيروئيدي وقد يُسبب تأثيرات جانبية خطيرة مثل: نزيف معدي معوي أو فشل كلوي، مما قد يؤدي إلى دخول المستشفى وحتى إلى نتائج مميتة.</p><p dir="RTL">&nbsp;تذكَّر أن إجمالي مدة مشاركة استخدام كيتورولاك تروميثامين عن طريق الفم وعن طريق الوريد أو عن طريق العضل من كيتورولاك تروميثامين يجب أن لا تتجاوز (الخمسة) أيام لدى البالغين. لا يوصى باستخدام كيتورولاك تروميثامين لدى المرضى من الأطفال. كذلك، قد يتم خلوص كيتورولاك تروميثامين ببطء أكبر من قبل كبار السن الذين هم أيضاً أكثر حساسية للتأثيرات الضارة المرتبطة بالجرعة من مضادات الالتهاب غير الستيروئيدية. يجب توخي الحذر الشديد والجرعات المخفضة والمراقبة السريرية الدقيقة عند معالجة كبار السن بدواء كيتورولاك تروميثامين.</p><p dir="RTL"><strong>تَوَقَّف</strong>&nbsp;عن تناول الدواء واحصل على الرعاية الطبية الطارئة&nbsp;<strong>على الفور</strong>&nbsp;إذا لاحظت أياً مما يلي:</p><p dir="RTL">&bull; براز دموي أو براز أسود.</p><p dir="RTL">&bull; ضيق تنفس, صفير, أية صعوبة في التنفس, أو ضيق في الصدر.</p><p dir="RTL">&bull; طفح جلدي, الشَّرى, تورم أو حكة.</p><p dir="RTL">&bull; رؤية غير واضحة, أو أي اضطراب في الرؤية.</p><p dir="RTL">&bull; أي تغيير في كمية أو لون بولك (أحمر أو بني).</p><p dir="RTL"><strong>تَوَقَّف</strong>&nbsp;عن تناول الأدوية وتحدث مع طبيبك أو الصيدلي إذا لاحظت أياً مما يلي:</p><p dir="RTL">&bull; أي ألم أو صعوبة تواجهك أثناء التبول.</p><p dir="RTL">&bull; تورم القدمين, أسفل الساقين, وزيادة الوزن.</p><p dir="RTL">&bull; قيء أو استمرار عسر هضم, غثيان, آلم معدة أو إسهال.</p><p dir="RTL">&bull; تغير لون الجلد أو العينين للأصفر، مع أو بدون حكة في الجلد.</p><p dir="RTL">&bull; شعور بضيق, تعب, وفقدان شهية.</p><p dir="RTL">&bull; صداع، تصلب بالرقبة.</p><p dir="RTL">&bull; ارتباك ذهني, واكتئاب.</p><p dir="RTL">&bull; دوار, دوخة.</p><p dir="RTL">&bull; مشاكل بالسمع.</p><p dir="RTL">هذه ليست قائمة كاملة بالتأثيرات الجانبية. للحصول على أية تأثيرات غير متوقعة أثناء تناول&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>، اتصل بطبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">&bull; العمر الافتراضي لهذا المنتج هو 24 شهراً. لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الكرتون والعبوة الزجاجية. يشير تاريخ انتهاء الصلاحية المذكور على العلبة والعبوة الزجاجية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ بدرجة حرارة دون 30&ordm; مئوية. احفظ الدواء في العلبة لحين وقت الاستخدام. يحفظ من الضوء.</p><p dir="RTL">&bull; لا تتخلص من أية أدوية عن طريق مياه الصرف أو في النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. فإن هذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة لهذا المنتج هي كيتورولاك تروميثامين.</p><p dir="RTL">&bull; المكونات الأخرى هي: إيثانول، كلوريد الصوديوم، حمض الهيدروكلوريك، هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن دواء&nbsp;<strong>كيتورولاك تروميثامين تي بي إم</strong>&nbsp;هو عبارة عن محلول رائق عديم اللون يميل قليلاً إلى اللون الأصفر، خالٍ من الجسيمات المرئية، مهيأ ضمن قارورات أنبوبية زجاجية بلون الكهرمان من النوع&nbsp;I&nbsp;سعة 2 مل، مغلقة بسدادات برومو بوتيل مطاطية رمادية داكنة 13 مم ومختومة بأختام ألمنيوم 13 مم .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الطبية الحيوية،</p><p dir="RTL">منطقة سُدير الصناعية,</p><p dir="RTL">سُدير،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            XXXX
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ketorolac Tromethamine TBM
Ketorolac Tromethamine Injection, USP 30 mg/mL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL contains 
Ketorolac Tromethamine…………30 mg
Excipients …. q.s.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection
A clear, colorless to slightly yellow color solution, free from visible particulates.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carefully consider the potential benefits and risks ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see section 4.4).</p><p><em>Acute Pain in Adult Patients</em></p><p>Ketorolac tromethamine TBM is indicated for the short-term (&le;5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.</p><p>The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see section 4.5, section 4.2, and section 4.8). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>In adults, the combined duration of use of IV or IM dosing of ketorolac tromethamine and oral ketorolac tromethamine is not to exceed 5 days.</strong></p><p><strong>In adults, the use of oral ketorolac tromethamine is only indicated as continuation therapy to IV or IM dosing of ketorolac tromethamine.</strong></p><p><strong>Note: Oral formulation</strong> should <strong>not </strong>be given as an initial dose</p><p><strong>Use minimum effective dose</strong> for the individual patient</p><p><strong>Total duration of treatment in adult patients:</strong> the combined duration of use of IV or IM dosing of ketorolac tromethamine and oral ketorolac tromethamine is not to exceed 5 days.</p><p>Ketorolac tromethamine TBM may be used as a single or multiple dose on a regular or &ldquo;prn&rdquo; schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Hypovolemia should be corrected prior to the administration of ketorolac tromethamine (see section 4.4). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.</p><p>When administering ketorolac tromethamine injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins in ~30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.</p><p><strong>Single-Dose Treatment: The following regimen should be limited to single administration use only</strong></p><p><strong>IM Dosing</strong></p><p>&bull; Patients &lt; 65 years of age: One dose of 60 mg.</p><p>&bull; Patients &ge; 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: One dose of 30 mg.</p><p><strong>IV Dosing</strong></p><p>&bull; Patients &lt; 65 years of age: One dose of 30 mg.</p><p>&bull; Patients &ge; 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: One dose of 15 mg.</p><p><strong>Multiple-Dose Treatment (IV or IM)</strong></p><p>&bull; Patients &lt; 65 years of age: The recommended dose is 30 mg Ketorolac Tromethamine TBM every 6 hours. The maximum daily dose for these populations should not exceed 120 mg.</p><p>&bull; For patients &ge; 65 years of age, renally impaired patients (see section 4.5), and patients less than 50 kg (110 lbs): The recommended dose is 15 mg ketorolac tromethamine injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg.</p><p>For breakthrough pain, do not increase the dose or the frequency of ketorolac tromethamine. Consideration should be given to supplementing these regimens with low doses of opioids &quot;prn&quot; unless otherwise contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ketorolac tromethamine TBM is contraindicated
• in patients with previously demonstrated hypersensitivity to ketorolac tromethamine.
• in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
• in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients Ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery.
• for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see section 4.4).
• in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see section 4.4).
• in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage.
• In patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see section 4.4).
• in nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates.
• In patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.
• for concomitant use with probenecid 
• for concomitant use with pentoxifylline 
• Ketorolac injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The most serious risks associated with ketorolac tromethamine are: Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation</strong>: Ketorolac&nbsp;tromethamine is contraindicated in patients with previously documented peptic ulcers and/or gastrointestinal (GI) bleeding. Ketorolac tromethamine can cause serious gastrointestinal (GI) adverse events including bleeding, ulceration and perforation, of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with ketorolac tromethamine.&nbsp;</p><p>Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Minor upper gastrointestinal problems, such as dyspepsia, are common and may also occur at any time during NSAID therapy.</p><p>The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with ketorolac tromethamine. Do not use ketorolac tromethamine for more than five days.</p><p>However, even short-term therapy is not without risk. In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.</p><p>To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of ketorolac tromethamine until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis, Crohn&rsquo;s disease) as their condition may be exacerbated.</p><p><strong>Hemorrhage</strong></p><p>Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet aggregation as well, use of ketorolac tromethamine in patients who have coagulation disorders should be undertaken very cautiously, and those patients should be carefully monitored. Patients on therapeutic doses of anticoagulants (e.g., heparin or dicumarol derivatives) have an increased risk of bleeding complications if given ketorolac tromethamine concurrently;&nbsp;therefore, physicians should administer such concomitant therapy only extremely cautiously. The concurrent use of ketorolac tromethamine and therapy that affects hemostasis, including prophylactic low-dose heparin (2500 to 5000 units q12h), warfarin and dextrans have not been studied extensively, but may also be associated with an increased risk of bleeding. Until data from such studies are available, physicians should carefully weigh the benefits against the risks, and use such concomitant therapy in these patients only extremely cautiously. Patients receiving therapy that affects hemostasis should be monitored closely. In postmarketing experience, postoperative hematomas and other signs of wound bleeding have been reported in association with the peri-operative use of IV or IM dosing of ketorolac tromethamine. Therefore, peri-operative use of ketorolac tromethamine should be avoided and postoperative use be undertaken with caution when hemostasis is critical (see section 4.4).</p><p><strong>Renal Effects</strong></p><p>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a NSAID may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p><p>Ketorolac tromethamine and its metabolites are eliminated primarily by the kidneys, which, in patients with reduced creatinine clearance, will result in diminished clearance of the drug (see section 5). Therefore, ketorolac tromethamine should be used with caution in patients with impaired renal function (see section 4.2) and such patients should be followed closely. With the use of ketorolac tromethamine, there have been reports of acute renal failure, interstitial nephritis and nephrotic syndrome</p><p><strong>Impaired Renal Function</strong></p><p>Ketorolac tromethamine is contraindicated in patients with serum creatinine concentrations indicating advanced renal impairment (see section 4.3). Ketorolac tromethamine should be used with caution in patients with impaired renal function or a history of kidney disease because it is a potent inhibitor of prostaglandin synthesis. Because patients with underlying&nbsp;renal insufficiency are at increased risk of developing acute renal decompensation or failure, the risks and benefits should be assessed prior to giving ketorolac tromethamine to these patients.</p><p><strong>Anaphylactoid Reactions</strong></p><p>As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ketorolac tromethamine. Ketorolac tromethamine should not be given to patients with the aspirin triad.</p><p>This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see section 4.3 and section 4.4). Emergency help should be sought in cases where an anaphylactoid reaction occurs.</p><p><strong>Cardiovascular Effects </strong></p><p><strong>Cardiovascular Thrombotic Events</strong></p><p>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal.</p><p>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</p><p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as ketorolac, increase the risk of serious gastrointestinal (GI) events (see section 4.4).</p><p><u>Status Post Coronary Artery Bypass Graft (CABG) Surgery</u></p><p>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10&ndash;14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [see section 4.3].</p><p><u>Post-MI Patients</u></p><p>Observational studies conducted in the Danish National Registry have demonstrated that&nbsp;patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CVrelated death, and all cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post MI was 20 per 100 person years in NSAIDtreated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.</p><p>Avoid the use of Ketorolac Tromethamine Injection in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Ketorolac Tromethamine Injection is used in patient with a recent MI, monitor patients for signs of cardiac ischemia.</p><p><strong>Hypertension</strong></p><p>NSAIDs, including ketorolac tromethamine, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ketorolac tromethamine, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p><p><strong>Heart Failure and Edema</strong></p><p>The Coxib and traditional NSAID Trialists&rsquo; Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.</p><p>In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.</p><p>Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of ketorolac tromethamine may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] [see section 4.4]</p><p>Avoid the use of ketorolac tromethamine Injection in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If Ketorolac&nbsp;Tromethamine Injection is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.</p><p><strong>Skin Reactions</strong></p><p>NSAIDs, including ketorolac tromethamine, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity</p><p><strong>Pregnancy</strong></p><p>In late pregnancy, as with other NSAIDs, ketorolac tromethamine should be avoided because it may cause premature closure of the ductus arteriosus.</p><p><em><strong>PRECAUTIONS</strong></em></p><p><em><strong>General</strong></em></p><p>Ketorolac tromethamine cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. The pharmacological activity of ketorolac tromethamine in reducing inflammation may diminish the utility of this diagnostic sign in detecting complications of presumed noninfectious, painful conditions.</p><p><strong>Hepatic Effects</strong></p><p>Ketorolac tromethamine should be used with caution in patients with impaired hepatic function or a history of liver disease. Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ketorolac tromethamine. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.</p><p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ketorolac tromethamine. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), ketorolac tromethamine should be discontinued.</p><p><strong>Haematological Effects</strong></p><p>Anemia is sometimes seen in patients receiving NSAIDs, including ketorolac tromethamine. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ketorolac tromethamine, should have their hemoglobin or haematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ketorolac tromethamine who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.</p><p><strong>Pre-existing Asthma</strong></p><p>Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross reactivity, including bronchospasm, between aspirin and other nonsteroidal antiinflammatory drugs has been reported in such aspirin-sensitive patients, ketorolac tromethamine should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing asthma.</p><p><em><strong>Laboratory Tests</strong></em></p><p>Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash etc.) or if abnormal liver tests persist or worsen, ketorolac tromethamine should be discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketorolac is highly bound to human plasma protein (mean 99.2%). There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.</p><p><strong>Warfarin, Digoxin, Salicylate, and Heparin</strong></p><p>The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels. Therapeutic concentrations of<em><strong> digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin and tolbutamide</strong></em> did not alter ketorolac tromethamine protein binding. In a study involving 12 adult volunteers, oral ketorolac tromethamine was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin. In another study, ketorolac tromethamine dosed IV or IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo. Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see section 4.4)</p><p>The effects of warfarin and NSAIDs, in general, on GI bleeding are synergistic, such that the users of both drugs together have a risk of serious GI bleeding higher than the users of either drug alone.</p><p><strong>Aspirin</strong></p><p>When ketorolac tromethamine is administered with aspirin, its protein binding is reduced, although the clearance of free ketorolac tromethamine is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ketorolac tromethamine and aspirin is not generally recommended because of the potential of increased adverse effects.</p><p><strong>Diuretics</strong></p><p>Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see section 4.4), as well as to assure diuretic efficacy.</p><p><strong>Probenecid</strong></p><p>Concomitant administration of oral ketorolac tromethamine and probenecid resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated.</p><p><strong>Lithium</strong></p><p>NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.</p><p><strong>Methotrexate</strong></p><p>NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p><p><strong>ACE Inhibitors /Angiotensin II Receptor Antagonists</strong></p><p>Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients. Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists.</p><p><strong>Antiepileptic Drugs</strong></p><p>Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine).</p><p><strong>Psychoactive Drugs</strong></p><p>Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).</p><p><strong>Pentoxifylline</strong></p><p>When ketorolac tromethamine is administered concurrently with pentoxifylline, there is an increased tendency to bleeding.</p><p><strong>Nondepolarizing Muscle Relaxants</strong></p><p>In postmarketing experience there have been reports of a possible interaction between ketorolac tromethamine IV/IM and nondepolarizing mus cle relaxants that resulted in apnea. The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied.</p><p><strong>Selective Serotonin Reuptake Inhibitors (SSRIs)</strong></p><p>There is an increased risk of gastrointestinal bleeding when s elective s erotonin reuptake inhibitors (SSRIs) are combined with NSAIDs. Caution should be used when NSAIDs are administered concomitantly with SSRIs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>The use of ketorolac tromethamine, as with any drug known to inhibit cyclooxygenase/ prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of infertility, withdrawal of ketorolac tromethamine should be considered.</p><p><strong>Pregnancy</strong></p><p>Reproduction studies have been performed during organogenesis using daily oral doses of ketorolac tromethamine at 3.6 mg/kg (0.37 times the human AUC) in rabbits and at 10 mg/kg (1.0 times the human AUC) in rats. Results of these studies did not reveal evidence of teratogenicity to the fetus. However, animal reproduction studies are not always predictive of human response.</p><p><strong>Breast-feeding</strong></p><p>Exercise caution when ketorolac is administered to a nursing woman. Available information has not shown any specific adverse events in nursing infants; however, instruct patients to contact their infants healthcare provider if they note any adverse events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patient may experience drowsiness, dizziness, vertigo, insomnia or depression with the use of ketorolac tromethamine. Therefore, patients should exercise caution in carrying out potentially hazardous activities that require alertness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reaction rates increase with higher doses of ketoralac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as G.I. ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see section 4.4 and section 4.2). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately.</p><p>Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Adverse reactions reported with tigecycline, including clinical trials and post-marketing experience</p><p><strong>Table 1: Reported adverse experiences in patients taking ketorolac tromethamine or other NSAIDs in clinical trials and rarely observed reactions (reported from postmarketing experience in patients taking Ketorolac tromethamine or other NSAIDs)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System&nbsp;Organ&nbsp;Class</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and</em></p><p><em>lymphatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;system disorders</em></p></td><td style="vertical-align:top"><p>anemia,</p></td><td style="vertical-align:top"><p>eosinophilia, leukopenia, thrombocytopenia</p></td><td style="vertical-align:top"><p>agranulocytosis, aplastic anemia,&nbsp;hemolytic&nbsp;anemia,&nbsp;lymphadenopathy,</p><p>pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>congestive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;heartfailure,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;palpitation,</p><p>pallor,&nbsp;&nbsp;&nbsp;&nbsp;tachycardia, syncope</p></td><td style="vertical-align:top"><p>arrhythmia,bradycardia, chest pain</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>tinnitus</p></td><td style="vertical-align:top"><p>hearing&nbsp;loss</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abnormal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vision,blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>abdominal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pain,constipation/diarrhea,&nbsp;dyspepsia,&nbsp;flatulence, GI&nbsp;fullness,&nbsp;GI&nbsp;ulcers&nbsp;(gastric/duodenal), gross&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bleeding/&nbsp;perforation,&nbsp;heartburn,&nbsp;nausea*,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stomatitis, vomiting,</p></td><td style="vertical-align:top"><p>anorexia,&nbsp;dry&nbsp;mouth,eructation, esophagitis,&nbsp;excessive thirst, gastritis, glossitis,&nbsp;haematemesis,hepatitis, increased appetite, jaundice, melena, rectal</p><p>bleeding,abnormal&nbsp;taste</p></td><td style="vertical-align:top"><p>acute pancreatitis, liver failure, ulcerative stomatitis,&nbsp;exacerbation&nbsp;of inflammatory bowel disease (ulcerative colitis, crohn&rsquo;s disease)</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>sweating,&nbsp;injection&nbsp;site&nbsp;pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>death</p></td></tr><tr><td style="vertical-align:top"><p><em>Investigations</em></p></td><td style="vertical-align:top"><p>elevated liver enzymes,&nbsp;increased bleeding time,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>asthma</p></td><td style="vertical-align:top"><p>hypersensitivityreactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue</p><p>edema.&nbsp;(see&nbsp;section&nbsp;4.4)</p></td></tr><tr><td style="vertical-align:top"><p><em>Infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;infestations</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fever,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;infections,sepsis, cystitis</p></td><td style="vertical-align:top"><p>conjunctivitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury,&nbsp;poisoning and procedural</em></p><p><em>complications</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>post-operative wound hemorrhage&nbsp;(see&nbsp;section</p><p>4.4)</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal&nbsp;and&nbsp;urinarydisorders</em></p></td><td style="vertical-align:top"><p>abnormal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;renalfunction,</p></td><td style="vertical-align:top"><p>dysuria,haematuria, increased urinary&nbsp;frequency,&nbsp;interstitial&nbsp;nephritis,&nbsp;oliguria/polyuria,&nbsp;proteinuria, renal</p><p>failure,&nbsp;urinary&nbsp;retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hemolytic&nbsp;uremic&nbsp;syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>epistaxis, cough, dyspnea, pulmonary edema, rhinitis</p></td><td style="vertical-align:top"><p>angioedema,bronchospasm,respiratory depression, pneumonia</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Reproductive&nbsp;system&nbsp;and&nbsp;breast</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infertility</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>edema</p></td><td style="vertical-align:top"><p>weight&nbsp;change</p></td><td style="vertical-align:top"><p>hyperglycemia,</p><p>hyperkalemia, hyponatremia</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal&nbsp;and connective</em></p><p><em>tissue&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myalgia, flank pain with or without&nbsp;haematuria&nbsp;and/or</p><p>azotemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;system disorders</em></p></td><td style="vertical-align:top"><p>dizziness,&nbsp;headache</p></td><td style="vertical-align:top"><p>abnormal dreams, abnormal thinking, anxiety, asthenia,&nbsp;confusion,&nbsp;depression,euphoria,extrapyramidal symptoms, hallucinations, hyperkinesis,&nbsp;inability to&nbsp;concentrate, insomnia, nervousness, paresthesia,&nbsp;somnolence, stupor, tremors, vertigo,</p><p>malaise</p></td><td style="vertical-align:top"><p>aseptic meningitis, convulsions,coma,&nbsp;psychosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension,myocardial infarction, vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneoustissue&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>pruritus,&nbsp;Purpura,&nbsp;Rashes</p></td><td style="vertical-align:top"><p>alopecia, photosensitivity, urticarial, ecchymosis</p></td><td style="vertical-align:top"><p>flushing, exfoliative dermatitis, erythema multiforme, Lyell&#39;s syndrome, bullous reactions including Stevens-Johnsonsyndrome and toxic epidermal</p><p>necrolysis</p></td></tr></tbody></table><p><strong>*Incidence&nbsp;greater&nbsp;than&nbsp;10%</strong></p><p>Postmarketing&nbsp;Surveillance&nbsp;Study</p><p>A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving ketorolac tromethamine, demonstrated that the risk of clinically serious gastrointestinal (GI) bleeding was dose-dependent (see Tables 2A and 2B). This was particularly&nbsp;true&nbsp;in&nbsp;elderly&nbsp;patients&nbsp;who&nbsp;received&nbsp;an&nbsp;average&nbsp;dailydose&nbsp;greater&nbsp;than&nbsp;60&nbsp;mg/day of ketorolac tromethamine (see Table 2A).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;2</strong></p><p><strong>Incidence&nbsp;of&nbsp;Clinically&nbsp;Serious&nbsp;G.I.&nbsp;Bleeding&nbsp;as&nbsp;Related&nbsp;to&nbsp;Age,&nbsp;Total&nbsp;Daily&nbsp;Dose,&nbsp;and</strong></p><p><strong>History&nbsp;of G.I.&nbsp;Perforation,&nbsp;Ulcer,&nbsp;Bleeding&nbsp;(PUB)&nbsp;after&nbsp;up&nbsp;to&nbsp;5&nbsp;Days&nbsp;of Treatmentwith Ketorolac Tromethamine Injection</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>A.&nbsp;Adult&nbsp;Patients&nbsp;without&nbsp;History&nbsp;of&nbsp;PUB</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Age&nbsp;of&nbsp;Patients</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Total&nbsp;Daily&nbsp;Dose&nbsp;of&nbsp;Ketorolac&nbsp;Tromethamine&nbsp;Injection</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;&nbsp;60&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;60 to 90&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;90 to 120&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;120&nbsp;mg</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;65&nbsp;years&nbsp;of&nbsp;age</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>0.9%</p></td><td style="vertical-align:top"><p>4.6%</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;65&nbsp;years&nbsp;of&nbsp;age</p></td><td style="vertical-align:top"><p>1.2%</p></td><td style="vertical-align:top"><p>2.8%</p></td><td style="vertical-align:top"><p>2.2%</p></td><td style="vertical-align:top"><p>7.7%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>B.&nbsp;Adult&nbsp;Patients&nbsp;with&nbsp;History&nbsp;of&nbsp;PUB</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Age&nbsp;of&nbsp;Patients</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Total&nbsp;Daily&nbsp;Dose&nbsp;of&nbsp;Ketorolac&nbsp;Tromethamine&nbsp;Injection</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;&nbsp;60&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;60 to 90&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;90 to 120&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>&gt;&nbsp;120&nbsp;mg</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt;65&nbsp;years&nbsp;of&nbsp;age</p></td><td style="vertical-align:top"><p>2.1%</p></td><td style="vertical-align:top"><p>4.6%</p></td><td style="vertical-align:top"><p>7.8%</p></td><td style="vertical-align:top"><p>15.4%</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;65&nbsp;years&nbsp;of&nbsp;age</p></td><td style="vertical-align:top"><p>4.7%</p></td><td style="vertical-align:top"><p>3.7%</p></td><td style="vertical-align:top"><p>2.8%</p></td><td style="vertical-align:top"><p>25.0%</p></td></tr></tbody></table><p>&nbsp;</p><p>Pediatric</p><p>Ketorolac tromethamine is not indicated for use in pediatric patients. The safety and effectiveness&nbsp;of&nbsp;ketorolactromethamine&nbsp;in&nbsp;pediatric&nbsp;patients&nbsp;below&nbsp;the&nbsp;age&nbsp;of&nbsp;17&nbsp;have&nbsp;not&nbsp;been&nbsp;established.</p><p>Other&nbsp;special&nbsp;population(s)</p><p><strong><em>Geriatric&nbsp;Use</em></strong></p><p>(&ge;65&nbsp;Years of&nbsp;Age)</p><p>Because ketorolac tromethamine may be cleared more slowly by the elderly (see section 5) who are also more sensitive to the dose-related adverse effects of NSAIDs (see section 4.4), extreme&nbsp;caution&nbsp;and&nbsp;reduced&nbsp;dosages(see&nbsp;section&nbsp;4.2)&nbsp;and&nbsp;careful&nbsp;clinical&nbsp;monitoring&nbsp;must&nbsp;be used when treating the elderly with ketorolac tromethamine.</p><p><strong>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</strong></p><p><u>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important.&nbsp;It&nbsp;allowscontinued&nbsp;monitoring&nbsp;of&nbsp;the&nbsp;benefit/risk&nbsp;balance&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product. Healthcare&nbsp;professionals&nbsp;are&nbsp;asked&nbsp;toreport&nbsp;any&nbsp;suspected&nbsp;adverse&nbsp;reactions to&nbsp;the&nbsp;competent authority in Saudi Arabia as per details below:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and&nbsp;Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC)</p><p><strong>o&nbsp;</strong>Fax:&nbsp;+966-11-205-7662</p><p><strong>o&nbsp;</strong>Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Exts:&nbsp;2317-2356-2353-2354-2334-2340.</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->Toll&nbsp;free&nbsp;phone:&nbsp;8002490000</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;www.sfda.gov.sa/npc</p><p>To report the Adverse event in other GCC States - Please contact the relevant competent&nbsp;authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms&nbsp;and&nbsp;Signs</strong></p><p>Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and&nbsp;coma&nbsp;may&nbsp;occur,&nbsp;but&nbsp;are&nbsp;rare.&nbsp;Anaphylactoidreactions&nbsp;have&nbsp;been&nbsp;reported&nbsp;with&nbsp;therapeutic ingestion of NSAIDs and may occur following an overdose.</p><p><strong>Treatment</strong></p><p>Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. There are no specific antidotes. Emesis and/or activated charcoal (60 g to 100 g in adults,&nbsp;1&nbsp;g/kg&nbsp;to&nbsp;2 g/kg&nbsp;in&nbsp;children)&nbsp;and/orosmotic&nbsp;cathartic&nbsp;may&nbsp;be&nbsp;indicated&nbsp;in&nbsp;patients&nbsp;seen&nbsp;within 4 hours of ingestion with symptoms or following a large oral overdose (5 to 10 times the&nbsp;usual&nbsp;dose).&nbsp;Forced&nbsp;diuresis,&nbsp;alkalization&nbsp;of&nbsp;urine,&nbsp;hemodialysis&nbsp;orhemoperfusion&nbsp;may&nbsp;not be useful due to high protein binding.</p><p>Single overdoses of ketorolac tromethamine have been variously associated with abdominal pain, nausea, vomiting, hyperventilation, peptic ulcers and/or erosive gastritis and renal dysfunction which have resolved after discontinuation of dosing.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;Group: Anti-inflammatory&nbsp;agents,&nbsp;non-steroids,&nbsp;ATC&nbsp;Code:&nbsp;<em>S01BC05</em></p><p><em>&nbsp;</em></p><p>Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs,&nbsp;is&nbsp;not&nbsp;completelyunderstood&nbsp;but&nbsp;may&nbsp;be&nbsp;related&nbsp;to&nbsp;prostaglandin&nbsp;synthetase&nbsp;inhibition.</p><p>The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.</p><p>The peak analgesic effect of ketorolac tromethamine occurs within 2 to 3 hours and is not statistically significantly different over the recommended dosage range of ketorolac tromethamine. The greatest difference between large and small doses of ketorolac&nbsp;tromethamine is in the duration of analgesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketorolac tromethamine is a racemic mixture of [-] S and [+] R-enantiomeric forms, with the S-form having analgesic activity.</p><p><strong>Comparison of IV, IM and Oral Pharmacokinetics:&nbsp;</strong>The pharmacokinetics of ketorolac tromethamine, following IV, IM and oral doses of ketorolac tromethamine are compared in Table&nbsp;3. In adults, the&nbsp;extent ofbioavailability&nbsp;following&nbsp;administration of&nbsp;the&nbsp;ORAL&nbsp;and IM forms of ketorolac tromethamine was equal to that following an IV bolus.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table&nbsp;3</strong></p><p><strong>Table of Approximate Average Pharmacokinetic Parameters (Mean &plusmn; SD) Following&nbsp;Oral,&nbsp;Intramuscular&nbsp;and&nbsp;Intravenous&nbsp;Doses&nbsp;of&nbsp;KetorolacTromethamine</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pharmacokinetic</p><p>Parameters</p></td><td style="vertical-align:top"><p>Oral*</p></td><td colspan="3" style="vertical-align:top"><p>Intramuscular&dagger;</p></td><td colspan="2" style="vertical-align:top"><p>Intravenous&nbsp;Bolus&Dagger;</p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;mg</p></td><td style="vertical-align:top"><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>30&nbsp;mg</p></td><td style="vertical-align:top"><p>60&nbsp;mg</p></td><td style="vertical-align:top"><p>15&nbsp;mg</p></td><td style="vertical-align:top"><p>30&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Bioavailability</p><p>(extent)</p></td><td colspan="6" style="vertical-align:top"><p>100%</p></td></tr><tr><td style="vertical-align:top"><p>Tmax1&nbsp;(min)</p></td><td style="vertical-align:top"><p>44&plusmn;34</p></td><td style="vertical-align:top"><p>33&plusmn;21&sect;</p></td><td style="vertical-align:top"><p>44&plusmn;29</p></td><td style="vertical-align:top"><p>33&plusmn;21&sect;</p></td><td style="vertical-align:top"><p>1.1&plusmn;0.7&sect;</p></td><td style="vertical-align:top"><p>2.9&plusmn;1.8</p></td></tr><tr><td style="vertical-align:top"><p>Cmax2&nbsp;(mcg/mL)&nbsp;[single-dose]</p></td><td style="vertical-align:top"><p>0.87&plusmn;0.22</p></td><td style="vertical-align:top"><p>1.14&plusmn;0.32&sect;</p></td><td style="vertical-align:top"><p>2.42&plusmn;0.68</p></td><td style="vertical-align:top"><p>4.55&plusmn;1.27&sect;</p></td><td style="vertical-align:top"><p>2.47&plusmn;0.51&sect;</p></td><td style="vertical-align:top"><p>4.65&plusmn;0.96</p></td></tr><tr><td style="vertical-align:top"><p>Cmax(mcg/mL)&nbsp;[steady&nbsp;state&nbsp;qid]</p></td><td style="vertical-align:top"><p>1.05&plusmn;0.26&sect;</p></td><td style="vertical-align:top"><p>1.56&plusmn;0.44&sect;</p></td><td style="vertical-align:top"><p>3.11&plusmn;0.87&sect;</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>3.09&plusmn;1.17&sect;</p></td><td style="vertical-align:top"><p>6.85&plusmn;2.61</p></td></tr><tr><td style="vertical-align:top"><p>3</p><p>Cmin&nbsp;mcg/mL)</p><p>[steady&nbsp;state&nbsp;qid]</p></td><td style="vertical-align:top"><p>0.29&plusmn;0.07&sect;</p></td><td style="vertical-align:top"><p>0.47&plusmn;0.13&sect;</p></td><td style="vertical-align:top"><p>0.93&plusmn;0.26&sect;</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>0.61&plusmn;0.21&sect;</p></td><td style="vertical-align:top"><p>1.04&plusmn;0.35</p></td></tr><tr><td style="vertical-align:top"><p>Cavg4&nbsp;(mcg/mL)&nbsp;[steady&nbsp;state&nbsp;qid]</p></td><td style="vertical-align:top"><p>0.59&plusmn;0.20&sect;</p></td><td style="vertical-align:top"><p>0.94&plusmn;0.29&sect;</p></td><td style="vertical-align:top"><p>1.88&plusmn;0.59&sect;</p></td><td style="vertical-align:top"><p>N/A</p></td><td style="vertical-align:top"><p>1.09&plusmn;0.30&sect;</p></td><td style="vertical-align:top"><p>2.17&plusmn;0.59</p></td></tr><tr><td style="vertical-align:top"><p>V&szlig;<sup>5</sup>&nbsp;(L/kg)</p></td><td colspan="4" style="vertical-align:top"><p>0.175&plusmn;0.039</p></td><td colspan="2" style="vertical-align:top"><p>0.210&plusmn;0.044</p></td></tr></tbody></table><p>%&nbsp;Dose&nbsp;metabolized =&nbsp;&lt;50 ; %&nbsp;Dose&nbsp;excreted&nbsp;in feces&nbsp;=&nbsp;6&nbsp;; %&nbsp;Dose&nbsp;excreted in&nbsp;urine&nbsp;=&nbsp;91 ;%&nbsp;Plasma&nbsp;protein binding&nbsp;=&nbsp;99</p><p>1Time-to-peak&nbsp;plasma&nbsp;concentration;&nbsp;<sup>2</sup>Peak&nbsp;plasma&nbsp;concentration;&nbsp;<sup>3</sup>Trough&nbsp;plasma&nbsp;concentration;&nbsp;<sup>4</sup>Average&nbsp;plasma concentration;&nbsp;<sup>5</sup>Volume of distribution</p><p>*Derived&nbsp;from&nbsp;PO&nbsp;pharmacokinetic&nbsp;studies&nbsp;in&nbsp;77&nbsp;normal&nbsp;fasted&nbsp;volunteers</p><p>&dagger;Derived&nbsp;from&nbsp;IM&nbsp;pharmacokinetic&nbsp;studies&nbsp;in&nbsp;54&nbsp;normal&nbsp;volunteers</p><p>&Dagger;Derived&nbsp;from&nbsp;IV pharmacokinetic&nbsp;studies&nbsp;in&nbsp;24&nbsp;normal&nbsp;volunteers</p><p>**Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent&nbsp;coefficient of variation for observed Cmax&nbsp;and Tmax&nbsp;data</p><p>&dagger;&dagger;Not&nbsp;applicable&nbsp;because&nbsp;60&nbsp;mg&nbsp;is&nbsp;only&nbsp;recommended&nbsp;as&nbsp;a&nbsp;single&nbsp;dose</p><p><strong>Linear&nbsp;Kinetics</strong></p><p>In&nbsp;adults,&nbsp;following&nbsp;administration&nbsp;of&nbsp;single&nbsp;ORAL,&nbsp;IM&nbsp;or&nbsp;IV&nbsp;doses&nbsp;of&nbsp;ketorolac&nbsp;tromethamine&nbsp;in&nbsp;therecommended&nbsp;dosage&nbsp;ranges,&nbsp;the&nbsp;clearance&nbsp;of&nbsp;the&nbsp;racemate&nbsp;does&nbsp;not&nbsp;change.&nbsp;This&nbsp;implies&nbsp;that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a proportional increase in the concentrations of free and bound&nbsp;racemate.</p><p><strong>Distribution</strong></p><p>The mean apparent volume (V&beta;) of ketorolac tromethamine following complete distribution&nbsp;was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, plasma concentrations as high as 10 mcg/mL will only occupy approximately 5% of the albumin binding sites.</p><p>Thus,&nbsp;the&nbsp;unbound&nbsp;fraction&nbsp;for&nbsp;each&nbsp;enantiomer&nbsp;will&nbsp;be&nbsp;constant&nbsp;over&nbsp;the&nbsp;therapeutic&nbsp;range.&nbsp;A decrease in serum albumin, however, will result in increased free drug concentrations.</p><p>Ketorolac&nbsp;tromethamine is&nbsp;excreted&nbsp;in&nbsp;human&nbsp;milk&nbsp;(see&nbsp;section&nbsp;4.4).</p><p><strong>Metabolism</strong></p><p>Ketorolac tromethamine is largely metabolized in the liver. The metabolic products are hydroxylated&nbsp;andconjugated&nbsp;forms&nbsp;of&nbsp;the&nbsp;parent&nbsp;drug.&nbsp;The&nbsp;products&nbsp;of&nbsp;metabolism,&nbsp;and&nbsp;some unchanged drug, are excreted in the urine.</p><p><strong>Excretion</strong></p><p>The principal route of elimination of ketorolac and its metabolites is renal. About 92% of a given dose is found in the urine, approximately 40% as metabolites and 60% as unchanged&nbsp;ketorolac.</p><p>Approximately&nbsp;6%&nbsp;of&nbsp;a&nbsp;dose&nbsp;is&nbsp;excreted&nbsp;in&nbsp;the&nbsp;feces.&nbsp;A&nbsp;single-dose&nbsp;study&nbsp;with&nbsp;10&nbsp;mg&nbsp;ketorolac tromethamine (n=9) demonstrated that the S-enantiomer is cleared approximately two times faster than the R-enantiomer and that the clearance was independent of the route of administration.&nbsp;This&nbsp;means&nbsp;that&nbsp;the&nbsp;ratio&nbsp;of&nbsp;S/R&nbsp;plasmaconcentrations&nbsp;decreases&nbsp;with&nbsp;time&nbsp;after&nbsp;each&nbsp;dose.&nbsp;There&nbsp;is&nbsp;little&nbsp;or&nbsp;no&nbsp;inversion&nbsp;of&nbsp;the&nbsp;R-&nbsp;to&nbsp;S-&nbsp;form&nbsp;in&nbsp;humans.&nbsp;The&nbsp;clearance&nbsp;of the racemate in normal subjects, elderly individuals and in hepatically and renally impaired patients is outlined in Table 4 (see section 5).</p><p>The&nbsp;half-life&nbsp;of&nbsp;the&nbsp;ketorolac&nbsp;tromethamine&nbsp;S-enantiomer&nbsp;was approximately&nbsp;2.5 hours&nbsp;(SD &plusmn; 0.4)&nbsp;compared with&nbsp;5&nbsp;hours&nbsp;(SD&nbsp;&plusmn;&nbsp;1.7)&nbsp;for&nbsp;the&nbsp;R-enantiomer. In&nbsp;other&nbsp;studies,&nbsp;the&nbsp;half-life&nbsp;for the racemate has been reported to lie within the range of 5 to 6 hours.</p><p><strong>Accumulation</strong></p><p>Ketorolac tromethamine administered as an IV bolus, every 6 hours for 5 days to healthy subjects (n = 13), showed no significant difference in C on Day 1 and Day 5. Trough levels averaged&nbsp;0.29&nbsp;mcg/mL&nbsp;(SD&nbsp;&plusmn;&nbsp;0.13)&nbsp;onDay&nbsp;1&nbsp;and&nbsp;0.55&nbsp;mcg/mL&nbsp;(SD&nbsp;&plusmn;&nbsp;0.23)&nbsp;on&nbsp;Day&nbsp;6.&nbsp;Steady state was approached after the fourth dose.</p><p>Accumulation&nbsp;of&nbsp;ketorolac&nbsp;tromethamine&nbsp;has&nbsp;not&nbsp;been&nbsp;studied&nbsp;in&nbsp;special&nbsp;populations&nbsp;(geriatric, pediatric, renal failure or hepatic disease patients).</p><p>Kinetics&nbsp;in&nbsp;Special&nbsp;Populations</p><p><strong>Geriatric&nbsp;Patients</strong>:&nbsp;Based&nbsp;on&nbsp;single-dose&nbsp;data&nbsp;only,&nbsp;the&nbsp;half-life&nbsp;of&nbsp;the&nbsp;ketorolac&nbsp;tromethamine racemate increased from 5 to 7 hours in the elderly (65 to 78 years) compared with young&nbsp;healthy&nbsp;volunteers&nbsp;(24&nbsp;to&nbsp;35years)&nbsp;(see&nbsp;Table&nbsp;4).&nbsp;There&nbsp;was&nbsp;little&nbsp;difference&nbsp;in&nbsp;the&nbsp;Cmax&nbsp;for&nbsp;the&nbsp;two groups (elderly, 2.52 mcg/mL &plusmn; 0.77; young, 2.99 mcg/mL &plusmn; 1.03) (see section 4.4).</p><p><strong>Pediatric&nbsp;Patients:&nbsp;</strong>Limited&nbsp;information&nbsp;is&nbsp;available&nbsp;regarding&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;dosing of ketorolac tromethamine in the pediatric population. Following a single intravenous bolus dose&nbsp;of&nbsp;0.5&nbsp;mg/kg&nbsp;in&nbsp;10&nbsp;children4&nbsp;to&nbsp;8&nbsp;years&nbsp;old,&nbsp;the&nbsp;half-life&nbsp;was&nbsp;5.8&nbsp;&plusmn;&nbsp;1.6&nbsp;hours,&nbsp;the&nbsp;average clearance&nbsp;was&nbsp;0.042&nbsp;&plusmn;&nbsp;0.01&nbsp;L/hr/kg,&nbsp;the&nbsp;volume&nbsp;ofdistribution&nbsp;during&nbsp;the&nbsp;terminal&nbsp;phase&nbsp;(V&beta;) was&nbsp;0.34&nbsp;&plusmn;&nbsp;0.12&nbsp;L/kg&nbsp;and&nbsp;the&nbsp;volume&nbsp;of&nbsp;distribution&nbsp;at&nbsp;steady&nbsp;state(Vss)&nbsp;was&nbsp;0.26&plusmn;&nbsp;0.08&nbsp;L/kg. The volume of distribution and clearance of ketorolac in pediatric patients was higher than those&nbsp;observed&nbsp;in&nbsp;adult&nbsp;subjects&nbsp;(see&nbsp;Table&nbsp;3).&nbsp;There&nbsp;are&nbsp;no&nbsp;pharmacokinetic&nbsp;data&nbsp;available&nbsp;for administration of ketorolac tromethamine by the IM route in pediatric patients.</p><p><strong>Renally Insufficiency:&nbsp;</strong>Based on single-dose data only, the mean half-life of ketorolac tromethamine&nbsp;in renallyimpaired patients is between 6 and 19 hours,&nbsp;and is dependent on the extent of the impairment. There is poor correlation between creatinine clearance and total ketorolac tromethamine clearance in the elderly and populations with renal impairment (r =&nbsp;0.5).&nbsp;In&nbsp;patients&nbsp;with&nbsp;renal disease,&nbsp;the&nbsp;AUC&infin;&nbsp;of&nbsp;each&nbsp;enantiomerincreased&nbsp;by&nbsp;approximately&nbsp;100% compared with healthy volunteers. The volume of distribution doubles for the S- enantiomer&nbsp;and&nbsp;increasesby&nbsp;1/5th&nbsp;for&nbsp;the&nbsp;R-enantiomer.&nbsp;The&nbsp;increase&nbsp;in&nbsp;volume&nbsp;of&nbsp;distribution of ketorolac tromethamine implies an increase in unbound fraction.</p><p>The AUC&infin;-ratio of the ketorolac tromethamine enantiomers in healthy subjects and patients&nbsp;remained similar, indicating there was no selective excretion of either enantiomer in patients compared to healthy subjects (see section 4.4).</p><p><strong>Hepatic Insufficiency:&nbsp;</strong>There was no significant difference in estimates of half-life, AUC&infin;&nbsp;and Cmax&nbsp;in 7 patients with liver disease compared to healthy volunteers (see section 4.4 and&nbsp;Table 4).</p><p><strong>Race:&nbsp;</strong>Pharmacokinetic&nbsp;differences&nbsp;due&nbsp;to&nbsp;race&nbsp;have&nbsp;not&nbsp;been&nbsp;identified.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;4</strong></p><p><strong>The&nbsp;Influence&nbsp;of Age,&nbsp;Liver&nbsp;and&nbsp;Kidney&nbsp;Function,&nbsp;on&nbsp;the&nbsp;Clearance</strong></p><p><strong>and&nbsp;Terminal&nbsp;Half-life&nbsp;of&nbsp;Ketorolac&nbsp;Tromethamine&nbsp;(IM<sup>1</sup>&nbsp;and&nbsp;ORAL<sup>2</sup>)&nbsp;in&nbsp;AdultPopulations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Total&nbsp;Clearance&nbsp;[in&nbsp;L/h/kg]<sup>3</sup></p></td><td colspan="2" style="vertical-align:top"><p>Terminal&nbsp;Half-life&nbsp;[in&nbsp;hours]</p></td></tr><tr><td style="vertical-align:top"><p>Type&nbsp;of&nbsp;Subjects</p></td><td style="vertical-align:top"><p>IM</p><p>Mean&nbsp;(range)</p></td><td style="vertical-align:top"><p>ORAL</p><p>Mean&nbsp;(range)</p></td><td style="vertical-align:top"><p>IM</p><p>Mean&nbsp;range)</p></td><td style="vertical-align:top"><p>ORAL</p><p>Mean&nbsp;range)</p></td></tr><tr><td style="vertical-align:top"><p>Normal&nbsp;Subjects IM (n=54)</p><p>mean&nbsp;age=32,&nbsp;range=18-60&nbsp;Oral (n=77) mean&nbsp;age=32,</p><p>range=20-60</p></td><td style="vertical-align:top"><p>0.023</p><p>(0.010-0.046)</p></td><td style="vertical-align:top"><p>0.025</p><p>(0.013-0.050)</p></td><td style="vertical-align:top"><p>5.3</p><p>(3.5-9.2)</p></td><td style="vertical-align:top"><p>5.3</p><p>(2.4-9)</p></td></tr><tr><td style="vertical-align:top"><p>Healthy&nbsp;Elderly&nbsp;Subjects IM (n=13), Oral (n=12)</p><p>mean&nbsp;age=72,&nbsp;range=65-78</p></td><td style="vertical-align:top"><p>0.019</p><p>(0.013-0.034)</p></td><td style="vertical-align:top"><p>0.024</p><p>(0.018-0.034)</p></td><td style="vertical-align:top"><p>7</p><p>(4.7-8.6)</p></td><td style="vertical-align:top"><p>6.1</p><p>(4.3-7.6)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with Hepatic&nbsp;Dysfunction IM and Oral (n=7) mean age=51,&nbsp;range=43-64</p></td><td style="vertical-align:top"><p>0.029</p><p>(0.013-0.066)</p></td><td style="vertical-align:top"><p>0.033</p><p>(0.019-0.051)</p></td><td style="vertical-align:top"><p>5.4</p><p>(2.2-6.9)</p></td><td style="vertical-align:top"><p>4.5</p><p>(1.6-7.6)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with Renal&nbsp;Impairment</p><p>IM&nbsp;(n=25),&nbsp;Oral&nbsp;(n=9)</p><p>serum&nbsp;creatinine=1.9-5.0&nbsp;mg/dL</p><p>mean&nbsp;age&nbsp;(IM)=54, range 35-71</p><p>mean&nbsp;age&nbsp;(Oral)=57,&nbsp;range=39-70</p></td><td style="vertical-align:top"><p>0.015</p><p>(0.005-0.043)</p></td><td style="vertical-align:top"><p>0.016</p><p>(0.007-0.052)</p></td><td style="vertical-align:top"><p>10.3</p><p>(5.9-19.2)</p></td><td style="vertical-align:top"><p>10.8</p><p>(3.4-18.9)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Renal&nbsp;Dialysis&nbsp;Patients IM and Oral (n=9) mean age=40,&nbsp;range=27-63. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></td><td style="vertical-align:top"><p>0.016 &nbsp;</p><p>(0.003-0.036)&nbsp;</p></td><td style="vertical-align:top"><p>- &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>13.6. &nbsp;</p><p>(8.0-39.1). &nbsp; &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>- &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></td></tr></tbody></table><p><sup>1</sup>Estimated from 30 mg single IM doses of ketorolac tromethamine&nbsp;<br /><sup>2</sup>Estimated&nbsp;from&nbsp;10&nbsp;mgsingle&nbsp;oral&nbsp;doses&nbsp;of&nbsp;ketorolac&nbsp;tromethamine&nbsp;<br /><sup>3</sup>Liters/hours/kilogram</p><p><strong>IV Administration:&nbsp;</strong>In normal subjects (n=37),&nbsp;the total clearance&nbsp;of&nbsp;30 mg IV-administered ketorolactromethamine&nbsp;was&nbsp;0.030&nbsp;(0.017&nbsp;to&nbsp;0.051)&nbsp;L/h/kg.&nbsp;The&nbsp;terminal&nbsp;half-life&nbsp;was&nbsp;5.6&nbsp;(4.0 to 7.9) hours. (See Kinetics in Special Population for use of IV dosing of ketorolac tromethamine in pediatric patients).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An 18-month study&nbsp;in mice with oral doses of ketorolac tromethamine tablets at 2 mg/kg/day (0.9 times the human systemic exposure at the recommended IM or IV dose of 30 mg qid, based on area-under-the plasma-concentration curve [AUC]), and a 24-month study&nbsp;in rats at 5 mg/kg/day (0.5 times the human AUC) showed no evidence of tumorigenicity.</p><p>Ketorolac&nbsp;tromethamine&nbsp;was&nbsp;not&nbsp;mutagenic&nbsp;in&nbsp;the&nbsp;Ames&nbsp;test,&nbsp;unscheduled&nbsp;DNA&nbsp;synthesis&nbsp;and repair, and in forward mutation assays. Ketorolac tromethamine did not cause chromosome&nbsp;breakage in the&nbsp;<em>in vivo&nbsp;</em>mouse micronucleus assay. At 1590 mcg/mL and at higher concentrations, ketorolac tromethamine increased the incidence of chromosomal aberrations in Chinese hamster ovarian cells.</p><p>Impairment&nbsp;of&nbsp;fertility&nbsp;did&nbsp;not&nbsp;occur&nbsp;in&nbsp;male&nbsp;or&nbsp;female&nbsp;rats&nbsp;at&nbsp;oral&nbsp;doses&nbsp;of&nbsp;9&nbsp;mg/kg&nbsp;(0.9&nbsp;times the human AUC) and 16 mg/kg (1.6 times the human AUC) of ketorolac tromethamine,&nbsp;respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol</p><p>Sodium Chloride</p><p>Hydrochloric&nbsp;Acid</p><p>Sodium&nbsp;Hydroxide</p><p>Water for&nbsp;Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketorolac Tromethamine TBM is a clear, colourless to slightly yellow colour solution, free from&nbsp;visibleparticulates,&nbsp;presented&nbsp;in&nbsp;2&nbsp;mL&nbsp;amber&nbsp;tubular&nbsp;Type&nbsp;I&nbsp;glass&nbsp;vial,&nbsp;stoppered&nbsp;with&nbsp;13 mm Dark Grey&nbsp;coloured bromo butyl rubber stoppers and sealed with 13 mm aluminium flip&nbsp;off seals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketorolac&nbsp;tromethamine&nbsp;TBM&nbsp;should&nbsp;not&nbsp;be&nbsp;mixed&nbsp;in&nbsp;a&nbsp;small&nbsp;volume&nbsp;(e.g.,&nbsp;in&nbsp;a&nbsp;syringe)&nbsp;with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride; this will result in precipitation of ketorolac from solution.</p><p><strong>NOTE</strong>: Parenteral drug products should be inspected visually for particulate matter and&nbsp;discoloration prior to administration, whenever solution and container permit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company,
Sudair Industrial Zone,
Sudair,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>